Article
Speaker Programs Still In The Crosshairs After All These Years: Lessons Learned Or Not
Takeda Pharmaceuticals agreed in May 2026 to pay $13,670,921 to resolve False Claims Act (“FCA”) allegations tied to its Trintellix speaker program.
Sheppard, Mullin, Richter & Hampton LLP
